The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Calza S.;
2019-01-01

Abstract

The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells
2019
2019
LS2_10 Bioinformatics
LS2_11 Computational biology
LS2_12 Biostatistics
LS7_3 Pharmacology, pharmacogenomics, drug discovery and design, drug therapy
Esperti anonimi
Inglese
Internazionale
10
1
2674
ADAM17 Protein; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Biomarkers, Tumor; Cell Line, Tumor; Computational Biology; Datasets as Topic; Drug Antagonism; Drug Resistance, Neoplasm; Drug Synergism; Genomics; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Pharmacogenetics; Phosphatidylinositol 3-Kinases; Treatment Outcome
http://www.nature.com/ncomms/index.html
354
info:eu-repo/semantics/article
262
Menden, M. P.; Wang, D.; Mason, M. J.; Szalai, B.; Bulusu, K. C.; Guan, Y.; Yu, T.; Kang, J.; Jeon, M.; Wolfinger, R.; Nguyen, T.; Zaslavskiy, M.; Aba...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
open
File in questo prodotto:
File Dimensione Formato  
491cfa9d-8b7e-0d1d-ab9d-6f0868e30e97.pdf

accesso aperto

Tipologia: Full Text
Licenza: Creative commons
Dimensione 1.61 MB
Formato Adobe PDF
1.61 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/524044
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 166
  • Scopus 270
  • ???jsp.display-item.citation.isi??? 243
social impact